Modifying the permeability of physiological barriers
AssigneeEisai Co., Ltd.
InventorsJames Martin Staddon, Mary Louise Morgan, Marianne Jennifer Ratcliffe
Life of this patent
Estimating the term…
Abstract
The degree of phosphorylation of serine and threonine residues of p100/p120 can affect the permeability of physiological barriers and also cell—cell adhesion properties. By changing physiological levels, various disorders can be treated, including multiple sclerosis, cancer, head injuries, oedema, stroke, inflammation and gastric ulcers. Furthermore, drugs can be allowed to pass across physiological barriers and the barriers can then be closed.
Claims24
A method of modifying the permeability of a physiological barrier comprising modifying the phosphorylation of serine or threonine residues of p100 and/or p120, by either
- (a) inducing the phosphorylation of serine and/or threonine residue of p100 and/or p120 with an agent capable of inducing the phosphorylation of serine and/or threonine residue of p100 and/or p120 to decrease the permeability of physiological barriers, or
- (b) inducing the dephosphorylation of phosphorylated serine and/or threonine residues of p100 and/or p120 with an agent capable of inducing the dephosphorylation of phosphorylated serine and/or threonine to increase the permeability of physiological barriers.
A method to decrease the permeability of the blood-brain barrier comprising administering an agent capable of inducing the phosphorylation of serine and/or threonine residue of p100 and/or p120.
A method to increase cell—cell adhesion comprising administering an agent capable of inducing the phosphorylation of serine and/or threonine residue of p100 and/or p120.
A method to increase the permeability of a physiological barrier comprising administering an agent capable of inducing the dephosphorylation of phosphorylated serine and/or threonine residue of p100 and/or p120.
Dependencies are inferred from the claim text.